Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-30

Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Phase 3 study of secukinumab in Ankylosing Spondylitis completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ankylosing Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-12-30